Trial reportPLoS neglected tropical diseases2018
Comparison of different drug regimens for the treatment of loiasis-A TropNet retrospective study.
Trial report in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Activity of antifilarial drugs on microfilaremia in the treatment of loiasis: a systematic review.Parasites & vectors · 2025Pooled it
- Guideline
- Efficacy and safety of albendazole 400 mg for 30 days compared to single dose of ivermectin in adult patients with low Loa loa microfilaremia: A non-inferiority randomized controlled trial.PLoS neglected tropical diseases · 2025Trial
- Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial.PLoS neglected tropical diseases · 2023Trial
- The impact of Loa loa microfilaraemia on research subject retention during a whole sporozoite malaria vaccine trial in Equatorial Guinea.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2022Trial
- Inequitable access to medicines for neglected tropical diseases in Europe: health system vulnerabilities and a call for coordinated action.The Lancet regional health. Europe · 2026Review
- Article
- Revisiting the Loa loa microfilaremia thresholds above which serious adverse events may occur with ivermectin treatment.PLoS neglected tropical diseases · 2025Article
- Article
- A Novel, Highly Sensitive Nucleic Acid Amplification Test Assay for the Diagnosis of Loiasis and its Use for Detection of Circulating Cell-Free DNA.The Journal of infectious diseases · 2023Article
- Loiasis from where you don't expect it: an illustrative case of misled diagnosis.Journal of travel medicine · 2022Article
- Colorimetric and Real-Time Loop-Mediated Isothermal Amplification (LAMP) for Detection ofDiagnostics (Basel, Switzerland) · 2022Article
- Infection-associated Immune Perturbations Resolve 1 Year Following Treatment for Loa loa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- [Loiasis: A tropical parasitosis in the Primary Care Clinic].Atencion primaria · 2020Article
- Loiasis in sub-Saharan migrants living in Spain with emphasis of cases from Equatorial Guinea.Infectious diseases of poverty · 2020Article
- Efficacy of High-Dose Albendazole with Ivermectin for Treating Imported Loiasis, Italy.Emerging infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLoa loa infection is endemic in limited areas of West-Central Africa. Loiasis has been associated with excess mortality, but clinical studies on its treatment are scant, particularly outside endemic areas, due to the rarity of cases diagnosed. METHODOLOGY/PRINCIPAL
findingsWith this retrospective TropNet (European Network for Tropical Medicine and Travel Health) study, we aimed at outlining the treatment schedules followed by different reference centers for tropical medicine across Europe. We gathered information about 238 cases of loiasis, 165 of which had follow up data. The regimens followed by the different centers were heterogeneous. The drugs most frequently administered were: diethylcarbamazine alone (74/165, 45.1%), ivermectin alone (41/165, 25%), albendazole + ivermectin (21/164, 11.6%), ivermectin + diethylcarbamazine (16/165, 9.7%). CONCLUSIONS/SIGNIFICANCE: The management of loiasis substantially differs across specialized travel clinics in Europe. These discrepancies could be due to different local protocols as well as to (un)availability of the drugs. An harmonization of clinical protocols for the treatment of loiasis would be suggested across reference centers for tropical medicine in Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.